IDNA vs VTI
iShares Genomics Immunology and Healthcare ETF vs Vanguard Morningstar Total Stock Market ETF
Which is better, IDNA or VTI?
Mid Cap Growth against Large Cap Blend.
VTI has a lower expense ratio. IDNA led over 1Y and 3Y, VTI over 5Y and the full window. VTI is less concentrated, with 33.5% of the fund in its ten largest positions against 48.3%.
MarketXLS is not an investment adviser. This comparison is generated automatically from market data and is for information only. A Best mark means the better reading on that one measure, not a recommendation to buy.
Side-by-Side Comparison
| Metric | IDNA | VTI |
|---|---|---|
| Expense Ratio | 0.47% | 0.03%Best |
| AUM | $310M | $689.2B |
| Dividend Yield | 0.66% | 1.06% |
| Holdings | 64 | 3,524 |
| YTD Return | +58.10%Best | +13.02% |
| 1Y Return | +72.03%Best | +16.63% |
| 3Y Return (annualized) | +30.33%Best | +21.97% |
| 5Y Return (annualized) | -2.47% | +11.99%Best |
| Volatility (annualized) | 26.0% | 16.8%Best |
| Max Drawdown | -68.3% | -35.0%Best |
| $10,000 over 5 years | $8,825 | $17,616Best |
| Top 10 Weight | 48.3% | 33.5%Best |
| Fund Family | iShares by BlackRock (US) | Vanguard (US) |
| Category | Equity | Equity |
| Style | Mid Cap Growth | Large Cap Blend |
| Inception | Jun 11, 2019 | May 24, 2001 |
Volatility and max drawdown are measured over the window both funds cover: Jun 13, 2019 to Oct 14, 2026 (7.3 years).
IDNA vs VTI growth
Month-end closes. Both lines start at 0% in the first month shown, so the gap between them is the difference in growth across that window. The full view covers the 7.3 years both funds cover.
IDNA vs VTI Performance
iShares Genomics Immunology and Healthcare ETF (IDNA) is an ETF from iShares by BlackRock (US) and Vanguard Morningstar Total Stock Market ETF (VTI) is an ETF from Vanguard (US). Over the past year IDNA returned +72.03% while VTI returned +16.63%. Year to date, IDNA is up 58.10% versus a gain of 13.02% for VTI.
Over three years, IDNA compounded at +30.33% per year against +21.97% for VTI; over five years the annualized figures are -2.47% and +11.99% respectively. Across the full 7-year window we track, VTI has the edge at +14.82% annualized vs +7.83%.
Past performance does not guarantee future results.
Risk: Volatility and Drawdowns
IDNA has been the more volatile fund, with annualized monthly volatility of 26.0% compared with 16.8% for VTI. Lower volatility generally means a smoother ride, though it often comes with lower long-run returns.
The deepest peak-to-trough decline in our data was -68.3% for IDNA and -35.0% for VTI. Drawdown depth is what each fund did in the worst stretch of the window measured above.
The two funds' monthly returns correlate at 0.59. They move together some of the time, and apart the rest.
Fees and Cost Over Time
IDNA charges 0.47% per year while VTI charges 0.03%. On a $10,000 position that is $47 vs $3 annually, a gap of $44 per year that compounds over a long holding period. On income, IDNA currently yields 0.66% against 1.06% for VTI.
Holdings Overlap
69.3% of IDNA's money is in holdings VTI also owns. 1.3% of VTI's money is in holdings IDNA also owns.
The two portfolios partly overlap.
33 positions in common, counted across the 50 positions we hold weights for in IDNA and 3,441 in VTI, against full books of 64 and 3,524.
What only one of them owns
Our book lists 1,145 positions for VTI that do not appear in our book for IDNA (96.3% of the fund), and 1 for IDNA that do not appear in VTI (0.1%).
Some of those will be the same company recorded under a different code in one of the two books, so the real difference in what you would own is no larger than this and may be smaller. We do not name the individual positions here for that reason.
Top Shared Holdings
| Stock | Weight in IDNA | Weight in VTI | Difference |
|---|---|---|---|
| MRNAModerna | 11.23% | 0.07% | 11.16% |
| TWSTTwist Bioscience Corp. | 7.66% | 0.01% | 7.65% |
| IOVAIovance Biotherapeutics Inc | 4.88% | 0.00% | 4.88% |
| RVMDRevolution Medicines Inc | 3.89% | 0.06% | 3.83% |
| MRKMerck & Co. Inc. | 3.36% | 0.49% | 2.87% |
| VRTXVertex Pharmaceuticals Inc - Common | 3.20% | 0.19% | 3.01% |
| REGNRegeneron Parmaceuticals Inc. | 3.26% | 0.11% | 3.15% |
| INCYIncyte Corp. | 3.23% | 0.03% | 3.20% |
| EXELExelixis Inc | 3.10% | 0.02% | 3.08% |
| IBRXImmunitybio Inc | 3.09% | 0.00% | 3.09% |
69.3% of IDNA is already inside VTI.
You probably hold more than these two. Add the rest and see how much of the whole book is the same companies twice.
Free for up to 10 holdings. No account needed.
Frequently Asked Questions
Which is cheaper, IDNA or VTI?
IDNA has an expense ratio of 0.47% while VTI charges 0.03%. VTI is the cheaper option, by $44 a year on a $10,000 investment.
Which performed better, IDNA or VTI?
Over the past year IDNA returned +72.03% vs +16.63% for VTI, so IDNA leads on 1-year performance. Over the longest common window we track (7 years), IDNA annualized +7.83% vs +14.82% for VTI. Past performance does not guarantee future results. This is information, not a recommendation.
Which is riskier, IDNA or VTI?
IDNA has been the more volatile fund at 26.0% annualized versus 16.8% for VTI. Worst drawdown: IDNA -68.3% vs VTI -35.0%.
Should I hold both IDNA and VTI?
IDNA and VTI have a monthly-return correlation of 0.59, so their returns are far enough apart for the mix to behave differently from either one alone. This is information, not a recommendation.
What is the holdings overlap between IDNA and VTI?
69.3% of IDNA's money is in holdings VTI also owns. 1.3% of VTI's is in holdings IDNA also owns. They hold 33 positions in common, counted across the 50 positions we hold weights for in IDNA and 3,441 in VTI.
Which pays a higher dividend, IDNA or VTI?
IDNA yields 0.66% while VTI yields 1.06%, so VTI currently pays the higher dividend yield.
Is VTI better than IDNA?
VTI has a lower expense ratio. IDNA led over 1Y and 3Y, VTI over 5Y and the full window. VTI is less concentrated, with 33.5% of the fund in its ten largest positions against 48.3%. Which one suits a particular account depends on what it is for. This is information, not a recommendation.